drugset
drugset / Trial / NCT03837093

Low-dose IL-2 to the Kinetics of Regulatory T-cell in Healthy Volunteers

NCT03837093 ↗

Phase 1 Completed 40 enrolled Assistance Publique - Hôpitaux de Paris Iltoo Pharma · collab
RandomizedParallel-groupDouble-blindOther

Summary

The purpose of this study is to evaluate the safety and the dose-response relationship of ILT-101 to blood Tregs.

Timeline

Start
2019-06-06
Primary completion
2021-03-03
Completion
2021-11-06

Drugs

EvaluationDrugModalityDoseRoute
Subject aldesleukin Protein / enzyme biologic — Subcutaneous

Indications

No indication recorded.